VTGN · Vistagen Therapeutics, Inc. · Analyst Estimates
$0.24
0.00 (-0.84%)
At close · Sep 11
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, we had cash, cash equivalents, and marketable securities of approximately $31.7 million. As of August 14, 2026, the issuance date of the condensed consolidated financial statements in this Quarterly Report as of and for the three months ended June 30, 2026, there is uncertainty about whether our combined cash, cash equivalents, and marketable securities will be sufficient to fund operations beyond twelve months from the issuance date of the condensed consolidated financial statements in this Report and therefore we concluded that substantial doubt exists about our ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$10.52M
Shares
44.38M
Analyst Estimates
Compare analyst forecasts for Vistagen Therapeutics, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Only independently verified consensus published through the company's investor-relations sources is available.
Consensus not yet available
Only independently verified consensus published through the company's investor-relations sources is available.
Key facts
CIK
1411685
CUSIP
92840H400
13F (30d)
22 filings
22 filers
Visit website
Investor relations